Intact human chorionic gonadotropin (hCG), hyperglycosylated hCG, and the free ␤ subunit are the forms of hCG produced by healthy tissues and tumors (1 ) . Intact hCG is the predominant form in serum and plasma in pregnancy and trophoblastic disease, hyperglycosylated hCG in choriocarcinoma and testicular cancer, and the free ␤ subunit in nongestational malignancy. Proteases present in macrophages associated with tumors or present in serum degrade these forms, resulting initially in nicked intact hCG, nicked hyperglycosylated hCG, and nicked free ␤ subunit. Nicked intact hCG rapidly dissociates into free nicked ␤ subunit and free ␣ subunit. The C-terminal peptide is cleaved, and further degradation results in the ␤-subunit core fragment (1 ) . All of these variants may be present in serum and urine, and an ideal hCG tumor marker assay would detect all of these products. Tumors that produce only free ␤ subunits can be most effectively detected by assays that specifically measure this form (2 ) . Detection of ␤-subunit core fragment in serum or plasma may not be important because concentrations are exceedingly low (3 ) .
In a recent review, the authors reported that the Siemens Immulite hCG assay is the only assay that is useful for all pregnancy, gestational trophoblastic disease, and cancer applications (1 ) . However, this conclusion is not supported by data from 2 recent studies in which WHO International Reference Reagents were used for all the major variant forms of hCG. These 2 studies revealed molar crossreactivities for the Roche hCGϩ␤ (also known as Roche Total hCG) assay as follows: nicked hCG (96% and 95.8%,), free ␤ (130% and 107.7%), nicked free ␤ (92% and 92.5%), and ␤-core fragment (33% and 38.6% ). Although recognition of the ␤-core fragment by the Roche assay was somewhat lower than by the Immulite (53%) and Immulite 2000 (63% and 68.3%), this finding is of importance only if the assay is to be used for measurements of hCG concentrations in urine (4, 5 ) .
We analyzed 191 patient serum samples submitted to 2 New Zealand diagnostic laboratories for tumor-marker hCG measurement using both the Roche hCGϩ␤ and the Immulite 2000 assays. Clinical information was available for 96 of the samples: 46 from patients with gestational trophoblastic disease, of which 76% were positive (Ͼ5 IU/L); 35 with germ-cell tumors (80% positive); 8 with unspecified gonadal tumors (50% positive); and 7 with other cancers (71% positive).
hCG concentrations in the samples varied from Ͻ1 to 373 000 IU/L, with the majority of results Ͻ1000 IU/L. The upper limit of the reference interval for serum hCG in our laboratories is 5 IU/L. Discrepant results were defined as those that were either Ͼ7 IU/L on Immulite and Ͻ4 IU/L on Roche assay, or Ͻ4 IU/L on Immulite and Ͼ7 IU/L on Roche assay; this definition was used in order not to classify as discrepant closely similar results that happened to lie on either side of the cutoff point. Among the 191 samples tested there was only 1 discrepant result (7.4 IU/L on Immulite and 3.4 IU/L on Roche assay).
The relationship between the 2 assays is shown in Fig. 1 . Weighted Deming-regression analysis of results Ͻ100 000 IU/L yielded the following equation: Roche hCG ϭ (0.85 ϫ Immulite hCG) Ϫ 0.57. Weighted Deming-regression analysis with a constant CV was performed by using Microsoft Excel with Analyze-it software.
In 1 patient with a hydatidiform mole, the initial hCG result measured on the Immulite was falsely low, owing to antigen excess 
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(high-dose hook effect). On this undiluted sample the Immulite assay gave the falsely low value of 3206 IU/L; the result after appropriate dilution was 667 000 IU/L. On the Roche assay, the same sample gave a result Ͼ10 000 IU/L (undiluted) and 893 900 after appropriate dilution, suggesting that the Immulite assay may be more prone to hook effect than the Roche assay.
These findings indicate that, for the set of samples we tested, the Roche hCGϩ␤ and Immulite hCG assays yield equivalent quantitative results when used on serum samples in the context of tumormarker testing.
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Overestimation of Serum Free Light Chain Concentration by Immunonephelometry
To the Editor:
We were interested to read the recent letter from de Kat Angelino et al. (1 ) and agree with many but not all of their conclusions.
We are, of course, aware that our assays report higher concentrations of free light chains (FLCs) than those measured by gel techniques, and these observations have been published on several occasions [e.g., (2-4 ) ]. Likewise, our own studies have indicated that this observation is more prevalent with monoclonal and is probably due to the presence of high molecular weight polymers.
Fractionation and analysis of sera from 2 patients with "nonsecretory" myeloma (3 ) suggested that the presence of variably sized polymers prevented the formation of a single clear band in a gel-leading to underestimation of the monoclonal FLCs. Conversely, the presence of polymerized FLCs enhanced the nephelometric reaction-leading to overestimation in comparison with the unpolymerized calibrator. For patients with very low levels of FLC production, who were previously thought to have nonsecretory myeloma, it is clear that the extra sensitivity provided by the nephelometric assay is advantageous.
Any nephelometric inaccuracies or imprecision due to polymerization will be minimized when monoclonal FLC production is low (e.g., when monitoring residual disease), but this situation occurs when densitometric measurements from electrophoresis gels will be less accurate because of the relatively higher background of polyclonal FLCs.
We also agree with the supposition (1 ) that the presence of polymers is likely to reduce the number of epitopes available for binding in an ELISA sandwich assay format and has the potential to lead to underestimates of the true amount of FLCs. In theory, the hiding of epitopes could reduce readings in a nephelometric assay, but in practice we have always seen overestimation, which presumably is due to facilitation of immune complex formation by the repeating epitopes in a polymer. This overestimation suggests that a truly accurate quantification of FLCs can be achieved only after complete dissociation of all polymers. In the absence of that, it would seem appropriate to treat all assay results with caution in terms of absolute accuracy.
One area of concern is the reference to the prognostic value of FLCs and the inference that moreaccurate assays are desirable for assessing prognosis. Serum FLC concentrations have now been reported to be prognostic in monoclonal gammopathies of undetermined significance, smoldering myeloma, multiple myeloma, amyloid light chain amyloidosis, and a number of other lymphoproliferative disorders [reviewed in (5 ) ], but all of these
